The Science of Parkinson's

Personal account of the Director of Research at @CureParkinsonsT - All views my own - Kiwi - Kia kaha - 侘寂

[The Science of Parkinson's @ScienceofPD]

Viral Desulfovibrio (DSV) species have been linked to #Parkinsons. Now researchers report that DSV-derived viability-dependent processes (including metabolic activity) more strongly promote alpha-synuclein aggregation & toxicity than structural component
https://t.co/mifwmvXMxf

[The Science of Parkinson's @ScienceofPD]

Movement disorders neurology remains an act of watching. @janealty1 & @vertigologist explore computer vision for the detection of deterioration in #Parkinsons. But if "no effective intervention or care response is available, have we actually helped"?
https://t.co/kVSdnMKW9a

[The Science of Parkinson's @ScienceofPD]

Mission Therapeutics @MISSIONTherapeu announces dosing of first #Parkinsons patient in the Phase 1b study of their USP30 inhibitor MTX325. The study is taking place in UK, Europe & Australia. Readout is anticipated in late 2027
https://t.co/mgM2bgLBKp

[The Science of Parkinson's @ScienceofPD]

Curiously, both of these ARBs are traditionally considered non-CNS penetrant

"both produce insurmountable, slowly reversible AT1 blockade with prolonged receptor residence times, whereas losartan binds in a surmountable, rapidly dissociating manner"

[The Science of Parkinson's @ScienceofPD]

Using large-scale hospital electronic health records of the University of California health system (n=890K hypertensive patients), researchers report Angiotensin receptor blockers irbesartan & olmesartan were associated with lower incident #Parkinsons risk
https://t.co/q9qVO7YNyI

[The Science of Parkinson's @ScienceofPD]

XellSmart presented 6 months post-transplant data for their Phase I trial of their off-the-shelf #Parkinsons cell therapy XS411, & announces successfully completion of enrollment for the Phase 2 trial of XS411
https://t.co/OEyLOCW29V

[The Science of Parkinson's @ScienceofPD]

Something researchers to explore: The GBA1 Canada initiative (G-can) - a pre-competitive, collaborative, open-science platform accelerating research & treatment development for GBA1-related #Parkinsons
https://t.co/4qOiyQVh1C

[The Science of Parkinson's @ScienceofPD]

New research suggests dietary patterns/habits in isolated REM sleep behavior disorder is associated with gut microbiome dysbiosis & predicts neurodegenerative progression, highlighting diet–microbiome interactions as modifiable factors
https://t.co/mDIkJPS79N

[The Science of Parkinson's @ScienceofPD]

Researchers virtually screen of 9.4k compounds (2.6k FDA-approved drugs, 6.7k African natural products) against the ATP-binding pocket of LRRK2-G2019S, & identify Rimonabant, Gallagic acid, Acalabrutinib, & Atovaquone as repurposable candidates
https://t.co/hcRuU5SbBF

[The Science of Parkinson's @ScienceofPD]

Researchers report a case of #Parkinsons caused by a de novo SNCA triplication with longitudinally evaluated gene expression in whole blood & platelets at 2 disease stages: early PD (age 41) & Parkinson's disease dementia (age 44)
https://t.co/beMEU3vSSe

[The Science of Parkinson's @ScienceofPD]

New research from the GP2 team finds that the GCH1 p.Ser80Asn variant is a rare, East Asian-enriched risk variant for #Parkinsons
https://t.co/YRuMHMNkR1

[The Science of Parkinson's @ScienceofPD]

Another week, another paper for @GeorgeTofaris & colleagues

This week, they report the epitope accessibility & topology of extracellular vesicle-associated α-synuclein proteoforms, rather than their abundance alone, discriminate synucleinopathy subtypes
https://t.co/4GUd4Qi4JQ

[The Science of Parkinson's @ScienceofPD]

New review explores resilience & vulnerability in the midbrain dopamine system during aging; "Elucidating these neuroadaptive mechanisms could offer a path toward preserving dopamine neuron function across the lifespan" & possibly preventing neurodegen.
https://t.co/65SJJgBYuc

[The Science of Parkinson's @ScienceofPD]

New editorial raises concerns about Vitamin B6 levels in #Parkinsons, & the need for monitoring them
https://t.co/hIBEBCfNl9

[The Science of Parkinson's @ScienceofPD]

Towards a better definition of patient-centered therapeutic strategy of #Parkinsons: A new opinion paper proposes "pragmatic, consensus-based principles for fully individualized, preference-sensitive pharmacological care across the patient journey"
https://t.co/BjuYsO6fLr

[The Science of Parkinson's @ScienceofPD]

Perspectives on ionizing radiation & #Parkinsons

"Emerging evidence from epidemiological studies in humans exposed to ionizing radiation (IR) suggests a positive association between IR & a specific neurological disorder, Parkinson’s"
https://t.co/VErEbUi3hn

[The Science of Parkinson's @ScienceofPD]

Results in the Parkinson's Precision Medicine Initiative (PPMI) indicate that a-synuclein-seed amplification assay testing results are highly consistent over time
https://t.co/6gdEPZr3R2

[The Science of Parkinson's @ScienceofPD]

"Artistic expression offers unique insights beyond structured assessments, fostering empathetic clinician–patient communication, & supporting a more holistic, person-centered approach to PD care". State of the “Art” in Freezing of Gait from @basbloem et al
https://t.co/xgRU5dk8WN

[The Science of Parkinson's @ScienceofPD]

The 2026 therapeutic development pipeline for Frontotemporal lobar degeneration has been published
https://t.co/ku7wOZyuO0

[The Science of Parkinson's @ScienceofPD]

"Intranigral AAV8-Irisin delivery did not produce statistically significant improvement in either motor performance or dopaminergic neuron survival" in a preclinical #Parkinsons (AAV9-A53T mouse) model. Peripheral AAV8-Irisin had no impact as well
https://t.co/KwOnaNuFbY